RedoxTherapies
Boston
About RedoxTherapies
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. Redox has compiled key assets in this space, including an exclusive license to vipadenant, a potent and selective A2a adenosine receptor antagonist, and intellectual property covering the combination of adenosine antagonists with immuno-modulatory agents.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Phone: (617)742-3055
Canonical: https://fsome.com/organization/redoxtherapies-1809317 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.